Galecto Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | DMRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDMRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.8x | −4.6x | −0.4x | |
PEG Ratio | −0.24 | 0.04 | 0.00 | |
Price / Book | 3.6x | 1.8x | 2.6x | |
Price / LTM Sales | - | 2.8x | 3.0x | |
Upside (Analyst Target) | 96.1% | 257.1% | 55.0% | |
Fair Value Upside | Unlock | 22.2% | 7.6% | Unlock |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.